LivaNova (NASDAQ:LIVN – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $3.10-$3.20 for the period, compared to the consensus EPS estimate of $3.09. LivaNova also updated its FY 2024 guidance to 3.100-3.200 EPS.
LivaNova Stock Performance
Shares of NASDAQ:LIVN traded down $1.34 during trading hours on Friday, hitting $46.98. The stock had a trading volume of 640,296 shares, compared to its average volume of 864,361. The stock’s fifty day simple moving average is $54.01 and its 200 day simple moving average is $54.39. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -78.30 and a beta of 0.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.71 and a current ratio of 3.45.
LivaNova (NASDAQ:LIVN – Get Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The business had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. During the same quarter last year, the business earned $0.43 earnings per share. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. Sell-side analysts anticipate that LivaNova will post 2.6 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on LivaNova
Insider Buying and Selling
In related news, Director Daniel Jeffrey Moore sold 56,623 shares of LivaNova stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $60.11, for a total value of $3,403,608.53. Following the transaction, the director now owns 27,534 shares in the company, valued at approximately $1,655,068.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
- Five stocks we like better than LivaNova
- Stock Market Sectors: What Are They and How Many Are There?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- 3 Fintech Stocks With Good 2021 Prospects
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.